Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
New treatments have extended the lives of many lung cancer patients. However, even better than treating lung cancer would be preventing it from developing in the first place.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Researchers from the Cedars-Sinai Heart Institute and the Cedars-Sinai Department of Medicine are expanding their ongoing evaluation of a novel cell-based therapeutic candidate into the area of pulmonary arterial hypertension (PAH).
Selexipag is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms.
Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.
Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.
Hepatoma-derived growth factor predicts disease severity and survival in patients with pulmonary arterial hypertension, showing some possible clinical advantages over N-terminal pro-brain natriuretic peptide, researchers report.
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs.
Serum asymmetric dimethylarginine may be an effective non-invasive screening biomarker for systemic sclerosis-related pulmonary arterial hypertension, study findings indicate.
Echocardiography re-assessment of right ventricular function after targeted therapy is sufficient to predict subsequent prognosis in patients with pulmonary arterial hypertension, say researchers.
Patients who develop pulmonary arterial hypertension as a consequence of systemic sclerosis have poorer right ventricular functional reserve than those with idiopathic disease, research published in Circulation shows.
Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers.
The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis.
Another meta-analysis adds to evidence of increased benefits for patients with pulmonary arterial hypertension who are given combination therapy.
Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today.
Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai.
A meta-analysis shows that clinical worsening is significantly less likely in patients with pulmonary arterial hypertension if they are given combination treatment, rather than monotherapy.
Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension.
Elevated levels of circulating bone morphogenetic protein 7 are associated with an increased mortality risk in patients with pulmonary arterial hypertension, find Chinese researchers.